임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

39건 표시

1/2상모집 예정· Solid Tumors
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
리드: GSK
상세 →NCT07602855
1/2상모집 중· Sarcoma
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
리드: GSK
상세 →NCT07602777
1/2상모집 예정· Lymphoma, Non-Hodgkin
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
리드: GSK
상세 →NCT07607925
1/2상모집 중· Respiratory Syncytial Virus Infections+Metapneumovirus
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
리드: GSK
상세 →NCT07628049
1/2상모집 중· Neoplasms, Prostate
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
리드: GSK
상세 →NCT07332455
1/2상모집 중· Gastrointestinal Cancer
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
협력: GSK
상세 →NCT07263594
1/2상모집 중· Lung Cancer, Non-Small Cell
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
리드: GSK
상세 →NCT06405230
1/2상모집 중· Neoplasms, Colorectal
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
리드: GSK
상세 →NCT07213609
1/2상모집 중· Neoplasms, Prostate
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
리드: GSK
상세 →NCT06990880
1/2상모집 중· Gastrointestinal Neoplasms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
리드: GSK
상세 →NCT06885034
1/2상모집 중단 (진행 중)· Melanoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
리드: GSK
상세 →NCT06521567
1/2상모집 중· Tumours, Gynecological
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
리드: GSK
상세 →NCT06796907
1/2상모집 중단 (진행 중)· Neoplasms, Colorectal
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
리드: GSK
상세 →NCT06710847
1/2상모집 중· Urinary Tract Infections
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
리드: GSK
상세 →NCT06702449
1/2상모집 중· Ovarian Cancer
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
협력: GSK, 일라이 릴리
상세 →NCT06594679
1/2상모집 예정· Glioma, Malignant
Niraparib and Temozolomide in Patients Glioblastoma
협력: GSK
상세 →NCT06258018
1/2상모집 중단 (진행 중)· Myeloid Leukemia
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
협력: GSK
상세 →NCT06235801
1/2상모집 중· AL Amyloidosis
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
협력: GSK
상세 →NCT05145816
1/2상모집 중단 (진행 중)· Recurrent Vulvovaginal Candidiasis
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
협력: GSK
상세 →NCT06190509
1/2상모집 중단 (진행 중)· Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
협력: GSK
상세 →NCT05784012
1/2상모집 중단 (진행 중)· Neoplasms
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
리드: GSK
상세 →NCT06077877
1/2상모집 중· Multiple Myeloma
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
협력: GSK
상세 →NCT05573802
1/2상모집 중· Multiple Myeloma
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
리드: GSK
상세 →NCT05714839
1/2상모집 예정· Breast Cancer
A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr
협력: GSK
상세 →NCT05519670
1/2상모집 예정· Multiple Myeloma
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
협력: GSK
상세 →NCT05581875
1/2상모집 중단 (진행 중)· Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
리드: GSK
상세 →NCT07150104
1/2상모집 중단 (진행 중)· Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
리드: GSK
상세 →NCT07150091
1/2상모집 중단 (진행 중)· Multiple Myeloma
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
협력: GSK
상세 →NCT05002816
1/2상모집 중단 (진행 중)· Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
리드: GSK
상세 →NCT07217184
1/2상모집 중단 (진행 중)· Multiple Myeloma
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
협력: 암젠, GSK
상세 →NCT04822337
1/2상모집 중단 (진행 중)· Multiple Myeloma
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
협력: GSK
상세 →NCT04808037
1/2상모집 중단 (진행 중)· Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
리드: GSK
상세 →NCT07084896
1/2상모집 중단 (진행 중)· Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
리드: GSK
상세 →NCT07217119
1/2상모집 중· Herpes Zoster
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
리드: GSK
상세 →NCT04006808
1/2상모집 중단 (진행 중)· Multiple Myeloma
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
리드: GSK
상세 →NCT04126200
1/2상모집 중단 (진행 중)· Relapsed and/or Refractory Multiple Myeloma
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
협력: GSK
상세 →NCT03715478
1/2상모집 중단 (진행 중)· Melanoma and Other Malignant Neoplasms of Skin
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
협력: GSK, 머크(MSD)
상세 →NCT03131908
1/2상모집 중단 (진행 중)· Glioblastoma Multiforme
Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
협력: GSK
상세 →NCT02331498
1/2상모집 중단 (진행 중)· Clear Cell Renal Cell Carcinoma
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
협력: GSK
상세 →NCT01684397

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.